期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄) |
日期 | |
1 | 曾浩翔(CHEN HAO XIANG)、黃志平(Chi-Ping Huang)*,Oncological and functional outcome of robotic-assisted radical cystectomy with total intracorporeal stentless J-pouch neobladder reconstruction,International Journal of Medical Robotics and Computer Assisted Surgery,2023 Oct,20(1):2583 | 2023 . 10 |
2 | 曾浩翔(CHEN HAO XIANG)、尤律婷(YU LU-TING)、張菡(Han Chang)、黃煒軒(Wei-Hsuan Huang)、林維卿(Wei-Ching Lin)、張兆祥(Chao-Hsiang Chang)*,Combined Immunotherapy and Tyrosine Kinase Inhibitor Treatment for Metastatic Renal Cell Carcinoma With Unknown Primary Origin: A Report of Two Cases and Literature Review,IN VIVO,2023 Jul,37(4):1905-1913 | 2023 . 07 |
3 | 曾浩翔(CHEN HAO XIANG)、蔡禮賢(Li-Hsien,Tsai)、張兆祥(Chao-Hsiang Chang)、吳錫金(Hsi-Chin Wu)、林精湛(Ching-Chan Lin)、林哲弘(Che-Hung Lin)、葉士芃(Shih-Peng Yeh)、連啟舜(Chi-Shun Lien)、楊啟瑞(Chi-Rei Yang)、張議徽(Yi-Huei Chang)、梁基安(Ji-An Liang)、陳冠亨(Guang-Heng Chen)、蕭博任(Po-Jen Hsiao)、謝博帆(Hsieh, Po-Fan)*、黃志平(Chi-Ping Huang)*,Enzalutamide prior to radium-223 is associated with better overall survival in metastatic castration-resistant prostate cancer patients compared to abiraterone - a retrospective study,Cancers,2023 Jul,15(13):3516-3516 | 2023 . 07 |
4 | 曾浩翔(CHEN HAO XIANG)、張詩欣(Shih-Hsin Chang)、陳得源(Der-Yuan Chen)、藍忠亮(Joung-Liang Lan)、楊凱介(Yeo Kai Jieh)、黃柏豪(Po-Hao Huang)、黃春明(Chung-Ming Huang)、黃志平(Chi-Ping Huang)、鄒頡龍(Chieh-Lung Chou)*、吳柏樟(Wu, Po-Chang)*,Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial,LUTS-Lower Urinary Tract Symptoms,2023 Apr,10(1111): | 2023 . 04 |
5 | 曾浩翔(CHEN HAO XIANG)、林精湛(Ching-Chan Lin)、林哲弘(Che-Hung Lin)、楊啟瑞(Chi-Rei Yang)*,Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report,Current Oncology,2023 Jan,30(1):326-332 | 2023 . 01 |
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目) |
日期 | |
1 | ,TICS2024泌尿國際研討會童綜合醫院,童綜合醫院,2024.05.31~2024.06.02,Mirabegron is better tolerated than solifenacin in Sjogren’s syndrome patients with overactive bladder symptoms | 2024 . 05 |
2 | Radium-223 after docetaxel has similar efficacy and safety profile compared to docetaxel naive in mCRPC patient,2023日本泌尿科醫學會年會,Kobe Conventional Center,2023.04.20~2023.04.23, | 2023 . 04 |
3 | Mirabegron is more tolerable than solifenacin in Sjogren’s syndrome patients with OAB,38th Annual European Association of Urology Congress,米蘭,2023.03.10~2023.03.13, | 2023 . 03 |
4 | Radium-223 for mCRPC: Real-world experience of a single-center,2021 台灣泌尿科醫學會年會,台中榮總,2021.12.25~2021.12.26, | 2021 . 12 |
5 | Ureteral stent does not reduce incidence of acute kidney injury in patient receiving radical cystectomy and ileal urinary diversion,2021 泌尿科醫學會半年會,基隆長庚,2021.04.10~2021.04.10, | 2021 . 04 |
6 | The role of tumor contact surface area and SPARE nephrometry in predicting malignancy and aggressiveness of clinical T1 tumors treated with partial nephrectomy,2022 International Session of TUA Conference,高雄醫學大學,2020.08.20~2020.08.20, | 2020 . 08 |
獲獎/Award (獲獎名稱,給獎單位,獲獎日期) |
日期 | |
1 | 優勝隊伍- 台灣泌尿科醫學會2023資深住院醫師學術辯論,台灣泌尿科醫學會,2023.8.19 | 2023 . 08 |
2 | 最佳辯士- 台灣泌尿科醫學會2023資深住院醫師學術辯論,台灣泌尿科醫學會,2023.8.19 | 2023 . 08 |